Cell Line Development Market Size & Share, by Product {Equipment (Incubators, Centrifuges, Bioreactors, Storage Equipment), Media & Reagents}; Cell Type (CHO Cells, BHK 21 Cells, NSO Cells, Murine C127 Cells, NIH3T3 Cells, L929 Cells); Application (Bioproduction, Tissue Engineering, Regenerative Medicine, Biologics); Industry (Biotechnology, Biopharma, Academia) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 713
  • Published Date: Dec 23, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Cell Line Development Market size was valued at USD 5.99 billion in 2024 and is expected to reach USD 20.92 billion by 2037, expanding at around 10.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of cell line development is assessed at USD 6.5 billion.

 The growth of the market can be attributed to the growing demand for monoclonal antibodies. These antibodies help to stimulate immune system. Thus they are extensively used for treating cancer, migraines, and more. Further, rising burden of cancer is expected to boost the market growth. According to the World Health Organization, Cancer is the most common cause of death worldwide, accounting for almost 10 million fatalities in 2020, or nearly one in every six deaths.

Moreover, rising need for vaccine production is anticipated to fuel the growth of the cell line development market. The cell line development technology is used in manufacturing various vaccines in order to treat viral infection such as HIV, influenza, and more. These vaccines prove to stimulate body immune system. Besides this, cell line technology has successful manufactured vaccine which could treat mild or moderate coronavirus. For a novel monoclonal antibody to treat COVID-19 that prevents the activity of the omicron variant, the US Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) in February 2022.


Get more information on this report: Request Free Sample PDF

Cell Line Development Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Burden of Osteoporosis:- According to the International Osteoporosis Foundation, every year, osteoporosis causes more than 8.9 million fractures worldwide, culminating in an osteoporosis fracture every 3 seconds.To deal with growing osteoporosis monoclonal antibodies are prepared which is known are stimulating antibodies in patient. Hence owing to this the market is expected to boost in the forecast period.
  • Growing Risk of Coronavirus: - As of February 2022, there had been approximate 5 million confirmed deaths due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, which has caused over 400 million cases.
  • Increasing Risk of Cancer Causing Disease:- According to the World Health Organization, about 30% of cancer cases in low- and lower-middle-income nations are caused by cancer-causing diseases such the human papillomavirus (HPV) and hepatitis.
  • Growing Nervous Systems Disorder Cases:- According to the European Academy of Neurology, over the past 30 years, the incidence of deaths from neurological disorders has climbed by approximately 40%, with 1 in 3 persons experiencing a neurological ailment at some point in their lives.
  • Cell Line Development Based On Mammalian Cell Culture;- Mammalian cell culture has recently become essential to the biomanufacturing of viral vaccines and therapeutic proteins. Through viral infection, these cells create vaccines, and through genetic engineering, they produce therapeutic proteins.

Challenges

  • Inability to Produce or Develop a Stable and Authentic Cell
  • Low Transfection Efficiency
  • Integration Frequency

Cell Line Development Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

10.1%

Base Year Market Size (2024)

USD 5.99 billion

Forecast Year Market Size (2037)

USD 20.92 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Cell Line Development Segmentation

The global cell line development market is segmented and analyzed for demand and supply by cell type into CHO cells, BHK 21 cells, NSO cells, murine C127 cells, NIH3T3 cells, L929 cells, and others. Out of which, BHK 21 cells segment is anticipated to garner the revenue share of 12.63% by the end of 2037, by growing at a highest CAGR of 12.84% during the forecast period. Increasing cases of rabies is expected to boost the market growth. BHK 21 cells are most frequently used cells lines. They are extensively used for treating rabies. The World Organization for Animal Health use these BHK21 cells in the regular diagnosis of rabies. To thrive in serum- or animal-component-free cell medium for the manufacture of rabies vaccines, BHK21 cells appear to have already undergone the necessary adaptations. Additionally CHO cells segment is anticipated to garner the largest revenue share of USD 27.89% by the end of 2036.

Our in-depth analysis of the global cell line development market includes the following segments:

By Product

  • Equipment
    • Incubators
    • Centrifuges
    • Bioreactors
    • Storage Equipment
    • Others
  • Media & Reagents

By Cell Type

  • CHO Cells
  • BHK 21 Cells
  • NSO Cells
  • Murine C127 Cells
  • NIH3T3 Cells
  • L929 Cells
  • Other Cells

By Application

  • Bioproduction
  • Tissue Engineering
  • Regenerative Medicine
  • Biologics
  • Medicines
  • Toxicity Testing
  • Research
  • Drug Discovery
  • Cell Therapies
  • Gene Therapies

By Industry

  • Biotechnology
  • Biopharma
  • Academia

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Cell Line Development Industry - Regional Synopsis

APAC Market Statistics

Regionally, the global cell line development market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in Asia Pacific is projected to hold the market share of USD 3,945.1 Million by the end of 2031, up from a revenue of USD 1,166.9 Million in the year 2021. Further, the market in Asia Pacific is expected to grow at the highest CAGR of 13.02% over the forecast period.

North America Market Analysis

North America industry is poised to dominate majority revenue share of 40% by 2037, backed by increasing investments and funds made available to manufacturing businesses and academic & research institutions to develop cell line-based end products like precision medicine and other treatments. In 2018, the National Institutes of Health's All of Us Research Program funded Genome Centers to generate genotype sequencing data from bio samples. To aid researchers in their quest to better understand how genetics, environment, and lifestyle choices affect health outcomes, they seek to create a varied network of more than 1 million participant partners across the US. In the upcoming years, it is anticipated that these factors will encourage market expansion.

Get more information on this report: Request Free Sample PDF

Companies Dominating the Cell Line Development Landscape

    • Lonza Group Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Thermo Fisher Scientific
    • Corning Incorporated
    • General Electric Company
    • Sartorius AG
    • Selexis SA
    • Merck KGaA
    • WuXi AppTec
    • others

In the News

  • Lonza Group Ltd. collaborates with Vineti to improve "Vein-to-Vein" delivery service across its manufacturing network for cell and gene therapy.
  • Moderna Inc. and Thermo Fisher Scientific signed a long-term agreement in February 2022 for the production of the COVID-19 vaccine and other investigational drugs based on mRNA technology.

Author Credits:  Radhika Pawar


  • Report ID: 713
  • Published Date: Dec 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of cell line development is assessed at USD 6.5 billion.

Cell Line Development Market size was valued at USD 5.99 billion in 2024 and is expected to reach USD 20.92 billion by 2037, expanding at around 10.1% CAGR during the forecast period i.e., between 2025-2037.

North America industry is poised to dominate majority revenue share of 40% by 2037, backed by increasing investments and funds made available to manufacturing businesses and academic & research institutions to develop cell line-based end products like precision medicine and other treatments.

The major players in the market are Lonza Group Ltd., Thermo Fisher Scientific, Corning Incorporated, General Electric Company, and more.
Cell Line Development Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample